Citations

Clear

224 citation(s) found for "Su, Jen-Jen".

Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer’s disease
Vermunt, Lisa , Dicks, Ellen , Wang, Guoqiao , Dincer, Aylin , Flores, Shaney , Keefe, Sarah , Berman, Sarah , Cash, David M. , Chhatwal, Jasmeer P. , Cruchaga, Carlos , Fox, Nick C. , Graff‐Radford, Neill R. , Hassenstab, Jason , Laske, Christoph , Xiong, Chengjie , Masters, Colin L. , Mori, Hiroshi , Morris, John C. , Noble, James M. , Perrin, Richard J. , Visser, Pieter Jelle , Bateman, Randall J. , Gordon, Brian A. , (DIAN), Dominantly Inherited Alzheimer Network, Amtashar, Fatima, Bodge, Courtney, Brandon, Susan E. , Buck, Jill , Buckles, Virginia, Chea, Sochenda, Chrem, Patricio, Chui, Helena C., Cinco, Jake, Jack, Clifford, D’Mello, Mirelle , Donahue, Tamara, Douglas, Jane, Edigo, Noelia, Erekin-Taner, Nilufer, Fagan, Anne M. , Farlow, Marty, Farrar, Angela, Feldman, Howard , Flynn, Gigi, Franklin, Erin , Gant, Cortaiga, Gardener, Samantha L. , Gray, Julia, Gurney, Jenny , Hassenstab, Jason, Hirohara, Mie, Hornbeck, Russ C. , DiBari, Siri Houeland, Ikonomović, Snežana, Jerome, Gina, Klunk, William E. , Kuder-Buletta, Elke, Marcus, Daniel S. , Mason, Neal Scott, Maue-Dreyfus, Denise, Montoya, Lucy, Nagamatsu, Akem, Neimeyer, Katie, Norton, Joanne, Raichle, Marc, Ringman, John M. , Roh, Jee Hoon , Shiroto, Tomoyo, Sigurdson, Wendy, Sparks, Paige, Swisher, Laura, Taddei, Kevin , Wang, Peter, Weiner, Mike, Wolfsberger, Mary, Xiong, Chengjie, Tijms, Betty M , Gordon, Brian A , Cruchaga, Carlos , Bateman, Randall J , Masters, Colin L , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Roh, Jee Hoon , Cash, David M , Feldman, Howard H , Berman, Sarah , Ghetti, Bernardino , Karch, Celeste M. , McDade, Eric , Schofield, Peter R. , Xiong, Chengjie , Scheltens, Philip , Benzinger, Tammie L.S. , Tijms, Betty M. , (DIAN), Dominantly Inherited Alzheimer Network, Allegri, Ricardo , Brandon, Susan, Brooks, William S. , Buck, Jill, Chui, Helena C. , Fujii, Hisako , Goate, Alison , Goldman, Jill , Hassenstab, Jason, Holtzman, David M. , Ikeuchi, Takeshi , Jucker, Mathias , Kasuga, Kensaku , Kawarabayashi, Takeshi , Koeppe, Robert A. , Martins, Ralph N. , Shimada, Hiroyuki , Shoji, Mikio , Sohrabi, Hamid R. , Suzuki, Kazushi , Wang, Jen Chin C. , Xiong, Chengjie, Xu, Xiong, Noble, James M

Mayo Clinic

Brain Communications | July 15, 2020 | Volume: 2 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcaa102 | PMID 32954344 Get It

Abstract Structural grey matter covariance networks provide an individual quantification of morphological patterns in the brain. The network integrity is disrupted in sporadic Alzheimer’s disease, and network properties show associations with the level of amyloid pathology and cognitive decline. Therefore, these network properties might be disease progression markers. However, it remains unclear when and how grey matter network integrity changes with disease progression. We investigated these questions in autosomal dominant Alzheimer’s disease mutation carriers, whose conserved age at dementia onset allows individual staging based upon their estimated years to symptom onset. From the Dominantly Inherited Alzheimer Network observational cohort, we selected T1-weighted MRI scans from 269 mutation carriers and 170 non-carriers (mean age 38 ± 15 years, mean estimated years to symptom onset −9 ± 11), of whom 237 had longitudinal scans with a mean follow-up of 3.0 years. Single-subject grey matter networks were extracted, and we calculated for each individual the network properties which describe the network topology, including the size, clustering, path length and small worldness. We determined at which time point mutation carriers and non-carriers diverged for global and regional grey matter network metrics, both cross-sectionally and for rate of change over time. Based on cross-sectional data, the earliest difference was observed in normalized path length, which was decreased for mutation carriers in the precuneus area at 13 years and on a global level 12 years before estimated symptom onset. Based on longitudinal data, we found the earliest difference between groups on a global level 6 years before symptom onset, with a greater rate of decline of network size for mutation carriers. We further compared grey matter network small worldness with established biomarkers for Alzheimer disease (i.e. amyloid accumulation, cortical thickness, brain metabolism and cognitive function). We found that greater amyloid accumulation at baseline was associated with faster decline of small worldness over time, and decline in grey matter network measures over time was accompanied by decline in brain metabolism, cortical thinning and cognitive decline. In summary, network measures decline in autosomal dominant Alzheimer’s disease, which is alike sporadic Alzheimer’s disease, and the properties show decline over time prior to estimated symptom onset. These data suggest that single-subject networks properties obtained from structural MRI scans form an additional non-invasive tool for understanding the substrate of cognitive decline and measuring progression from preclinical to severe clinical stages of Alzheimer’s disease.
NCCN Guidelines Insights: Rectal Cancer, Version 6.2020
Benson, Al B. , Al-Hawary, Mahmoud M. , Arain, Mustafa A., Chen, Yi‐Jen , Ciombor, Kristen K. , Cooper, Harry S. , Deming, Dustin A. , Garrido‐Laguna, Ignacio , Grem, Jean L. , Hoffe, Sarah E. , Hunt, Steven R., Kirilcuk, Natalie, Krishnamurthi, Smitha , Messersmith, Wells A. , Meyerhardt, Jeffrey A. , Miller, Eric D. , Mulcahy, Mary F. , Nurkin, Steven, Overman, Michael J. , Patel, Hitendra , Pedersen, Katrina S. , Shibata, David , Skibber, John M., Sofocleous, Constantinos T. , Stotsky‐Himelfarb, Eden, Willett, Christopher G. , Johnson-Chilla, Alyse, Gurski, Lisa A., Hubbard, Joleen, Miller, Eric D. , Meyerhardt, Jeffrey A , Pedersen, Katrina , Venook, Alan P. , Cohen, Stacey A. , Gunn, Andrew, Hubbard, Joleen M. , Parikh, Aparna R. , Patel, Hitendra, Saltz, Leonard B. , Schneider, Charles John , Stoffel, Elena M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 7, 2020 | Volume: 18 | Issue: 7 | Pages: 806-815

10.6004/jnccn.2020.0032 | PMID 32634771 Get It

The NCCN Guidelines for Rectal Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with rectal cancer. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines. These updates include clarifying the definition of rectum and differentiating the rectum from the sigmoid colon; the total neoadjuvant therapy approach for localized rectal cancer; and biomarker-targeted therapy for metastatic colorectal cancer, with a focus on new treatment options for patients with BRAF V600E– or HER2 amplification–positive disease.
Variation in Fluid and Vasopressor Use in Shock With and Without Physiologic Assessment: A Multicenter Observational Study
Chen, Jen‐Ting , Roberts, Russel J. , Qadir, Nida , Cairns, Charles B. , Mathews, Kusum S. , Park, Pauline, Khan, Akram , Gilmore, James F. , Brown, Anne Rain , Tsuei, Betty J., Handzel, Michele, Chang, Alfredo Lee, Herbert, James T. , Martinez, Anthony , Tonna, Joseph E. , Nazer, Lama , Heavner, Mojdeh S. , Pender, Erin, Chambers, Lauren, Kenes, Michael T. , Kaufman, David A. , Downey, April, Chaykosky, Darlene, Wolff, Armand, Smith, Michael , Nault, Katie, Sevransky, Jonathan, Gong, Michelle N. , Network, on behalf of the VOLUME-CHASERS Study Group and Society of Critical Care Medicine Discovery, Tonna, Joseph E. , Heavner, Mojdeh S , Khan, Akram , Fazzari, Melissa J. , Kashani, Kianoush , Park, Pauline K. , Duggal, Abhijit , Lanspa, Michael J. , Ammar, Mahmoud A , Hammond, Drayton A , Brown, Brent , Network, on behalf of the VOLUME-CHASERS Study Group and Society of Critical Care Medicine Discovery

Mayo Clinic

Critical Care Medicine | June 30, 2020 | Volume: 48 | Issue: 10 | Pages: 1436-1444

10.1097/ccm.0000000000004429 | PMID 32618697 Get It

Objectives: To characterize the association between the use of physiologic assessment (central venous pressure, pulmonary artery occlusion pressure, stroke volume variation, pulse pressure variation, passive leg raise test, and critical care ultrasound) with fluid and vasopressor administration 24 hours after shock onset and with in-hospital mortality. Design: Multicenter prospective cohort study between September 2017 and February 2018. Settings: Thirty-four hospitals in the United States and Jordan. Patients: Consecutive adult patients requiring admission to the ICU with systolic blood pressure less than or equal to 90 mm Hg, mean arterial blood pressure less than or equal to 65 mm Hg, or need for vasopressor. Interventions: None. Measurement and Main Results: Of 1,639 patients enrolled, 39% had physiologic assessments. Use of physiologic assessment was not associated with cumulative fluid administered within 24 hours of shock onset, after accounting for baseline characteristics, etiology and location of shock, ICU types, Acute Physiology and Chronic Health Evaluation III, and hospital (beta coefficient, 0.04; 95% CI, −0.07 to 0.15). In multivariate analysis, the use of physiologic assessment was associated with a higher likelihood of vasopressor use (adjusted odds ratio, 1.98; 95% CI, 1.45−2.71) and higher 24-hour cumulative vasopressor dosing as norepinephrine equivalent (beta coefficient, 0.37; 95% CI, 0.19−0.55). The use of vasopressor was associated with increased odds of in-hospital mortality (adjusted odds ratio, 1.88; 95% CI, 1.27−2.78). In-hospital mortality was not associated with the use of physiologic assessment (adjusted odds ratio, 0.86; 95% CI, 0.63−1.18). Conclusions: The use of physiologic assessment in the 24 hours after shock onset is associated with increased use of vasopressor but not with fluid administration.
Aberrant immunohistochemical expression of CD4 as a rare finding in metastatic melanoma
Chatzopoulos, Kyriakos , O’Brien, Daniel R. , Khazaie, Khashayarsha , Jen, Jin , Kocher, Jean‐Pierre , Flotte, Thomas J. , Sotiriou, Sotiris, Sotiriou, Sotiris , Markovic, Svetomir N.

Mayo Clinic

Journal of Cutaneous Pathology | June 28, 2020 | Volume: 47 | Issue: 12 | Pages: 1223-1226

10.1111/cup.13792 | PMID 32594533 Get It

Validation and Disease Risk Assessment of Previously Reported Genome-Wide Genetic Variants Associated With Brugada Syndrome
Liu, Yen‐Bin , Chen, Ching‐Yu Julius, Yu, Qi-You , Chattopadhyay, Amrita , Lin, Lian-Yu, Chen, Wen‐Jone , Yu, Chih-Chien, Huang, Hui‐Chun , Liao, Min‐Tsun , Yeh, Shih-Fan Sherri, Chuang, Jing‐Yuan, Yang, Dun-Hui, Lin, Jiunn‐Lee, Lu, Tzu‐Pin , Ackerman, Michael J. , Juang, Jyh‐Ming Jimmy , Ho, Li‐Ting , Lai, Ling‐Ping , Hwang, Juey‐Jen , Lin, Ting‐Tse , Chen, Jien‐Jiun , Chuang, Eric Yao-Yu

Mayo Clinic

Circulation: Genomic and Precision Medicine | June 3, 2020 | Volume: 13 | Issue: 4 | Pages: No page available

10.1161/circgen.119.002797 | PMID 32490690 Get It

Background: Brugada syndrome (BrS) is an oligogenic arrhythmic disease with increased risk of sudden cardiac arrest. Several BrS or ECG traits-related single-nucleotide polymorphisms (SNPs) were identified through previous genome-wide association studies in white patients. We aimed to validate these SNPs in BrS patients in the Taiwanese population, assessing the cumulative effect of risk alleles and the BrS-polygenic risk score in predicting cardiac events. Methods: We genotyped 190 unrelated BrS patients using the TWB Array, and Taiwan Biobank was used as controls. SNPs not included in the array were imputed by IMPUTE2. Cox proportional hazards model was used to evaluate the associations between each particular SNP, the collective BrS-polygenic risk score, and clinical outcomes. Results: Of the 88 previously reported SNPs, 22 were validated in Taiwanese BrS patients ( P <0.05). Of the 22 SNPs, 2 (rs10428132 and rs9388451) were linked with susceptibility to BrS, 10 were SNPs previously reaching genome-wide significance, and 10 were SNPs associated with ECG traits. For the 3 most commonly reported SNPs, disease risk increased consistently with the number of risk alleles (odds ratio, 3.54; P trend =1.38×10 −9 for 5 risk alleles versus 1). Similar patterns were observed in both SCN5A mutation+ (odds ratio, 3.66; P trend =0.049) and SCN5A mutation− (odds ratio, 3.75; P trend =8.54×10 −9 ) subgroups. Furthermore, BrS patients without SCN5A mutations had more risk alleles than BrS patients with SCN5A mutations regardless of the range of polygenic risk scores. Three SNPs (rs4687718, rs7784776, and rs2968863) showed significant associations with the composite outcome (sudden cardiac arrest plus syncope, hazard ratio, 2.13, 1.48, and 0.41; P =0.02, 0.006, and 0.008, respectively). Conclusions: Our findings suggested that some SNPs associated with BrS or ECG traits exist across multiple populations. The cumulative risk of the BrS-related SNPs is similar to that in white BrS patients, but it appears to correlate with the absence of SCN5A mutations.
A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma.
Mateos, María‐Victoria , Hong, Wan‐Jen , Cooper, Scott, Yu, Yao , Jalaluddin, Muhammad, Karve, Sudeep, Coppola, Sheryl , Maciag, Paulo , Bueno, Orlando F. , Arriola, Emma, Kumar, Shaji , Moreau, Philippe , Dimopoulos, Meletios Α. , Jalaluddin, Muhammad, Ross, Jeremy A.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: TPS8554-TPS8554

10.1200/jco.2020.38.15_suppl.tps8554 Get It

TPS8554 Background: BCL-2 is an anti-apoptotic protein important for myeloma cell survival. Venetoclax (Ven) is a highly selective, potent, oral BCL-2 inhibitor, that has shown promise in clinical studies as monotherapy or in combination with other agents in patients with t(11;14)-positive relapsed/refractory multiple myeloma (RRMM; Kumar et al. Blood. 2017; Costa et al. ASH 2018. Abstr. #303; Harrison et al. ASH 2019. Abstr. #142; Bahlis et al. ASH 2019. Abstr. #925; Kaufman et al. ASH 2019. Abstr. #926). Notably, t(11;14)-positive MM is more dependent on BCL-2 for cell survival, which, together with these clinical data, suggests that Ven combined with dexamethasone (Dex) may provide greater clinical benefit versus standard therapies, like pomalidomide (Pom), in this biomarker-defined patient population. This ongoing Phase 3 study (CANOVA; NCT03539744) aims to evaluate the safety and efficacy of VenDex vs PomDex in t(11;14)-positive RRMM. Methods: Eligible patients (≥18 years) must have t(11;14)-positive RRMM per central lab, an ECOG performance status ≤2, received ≥2 prior lines of therapy, previously received a proteasome inhibitor, and must be refractory to lenalidomide and last line of therapy. Patients cannot have history of treatment with Ven, Pom, or other BCL-2 inhibitors. Patients will be randomized 1:1 to Ven (800 mg orally, once-daily) or Pom (4 mg orally, once-daily on days 1-21 of 28-day cycles). Patients in both groups will receive 40 mg Dex (20 mg for patients ≥75 years) once weekly. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal from study. Patients will be stratified based on age at randomization ( < 65 vs ≥65 years), prior lines of therapy (2 to 3 vs ≥4), and International Staging System stage at screening (I vs II vs III). The primary endpoint is progression-free survival (PFS) per independent review committee (IRC) assessment based on International Myeloma Working Group criteria. The final PFS analysis will be performed when approximately 147 PFS events per IRC are observed. Secondary endpoints are response rate, patient-reported outcomes, overall survival, duration of response, times to response and progression, minimal residual disease negativity rate, safety, and Ven pharmacokinetics. Approximately 244 patients will be enrolled; as of January 21, 2020, 28 patients have been randomized (from 19 sites in 12 countries) and enrollment is ongoing. Clinical trial information: NCT03539744 .
Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses.
Popat, Rakesh , Suzuki, Kenshi , Kim, Inho , Spencer, Andrew , Hong, Wan‐Jen , Jalaluddin, Muhammad, Pauff, James M., Maciag, Paulo , Kumar, Shaji , Moreau, Philippe , Harrison, Simon J , Cavo, Michèle , Rubia, Javier de la , Popat, Rakesh , Hungria, Vânia , Salwender, Hans Jürgen , O’Dwyer, Michael , Jalaluddin, Muhammad, Yang, Xiaoqing , Ross, Jeremy A.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 8547-8547

10.1200/jco.2020.38.15_suppl.8547 Get It

8547 Background: Venetoclax (Ven) is a selective, potent BCL-2 inhibitor that has synergistic activity with bortezomib (B) and dexamethasone (d). In the Phase 3 BELLINI trial, addition of Ven to Bd significantly improved median progression-free survival (PFS) and response rates, including minimal residual disease (MRD) negativity, but resulted in increased mortality vs placebo (Pbo). Here, we determine whether MRD negativity was associated with longer PFS and OS in relapsed/refractory multiple myeloma (RRMM) patients treated with Ven+Bd in the BELLINI dataset. Methods: In BELLINI (NCT02755597), RRMM patients (pts) sensitive or naïve to proteasome inhibitors with 1-3 prior lines of therapy were randomized 2:1 to Ven (800 mg) or Pbo plus B (1.3 mg/m2) and d (20 mg). Next-gen sequencing MRD assessments were done on bone marrow aspirates at the time of suspected CR/sCR, and 6- and 12-months post confirmation of CR/sCR. Patients with a missing or indeterminate assessment were considered MRD positive. Evaluation of MRD in biomarker-defined subgroups (cytogenetics and BCL2 expression) was also performed and will be presented. Results: In total, 291 pts were randomized; 194 to Ven, 97 to Pbo. As of 13 Sep 2019, the median follow-up was 29 months. Ven + Bd demonstrated significantly higher MRD negativity rates ( < 10−5), including a higher proportion of pts achieving sustained MRD negativity (Table). In the Ven arm, the median (m)PFS was not reached for MRD negative pts vs 16.2 months for MRD positive pts (HR = 0.23, 95% CI: 0.10-0.54, p < 0.001). While the mOS was not reached in the Ven arm, OS was significantly longer for MRD negative vs MRD positive pts (HR = 0.25, 95% CI: 0.08-0.80, p = 0.0194). Conclusions: The addition of Ven to Bd resulted in deep and durable responses, including higher rates of MRD negativity. MRD negativity in the context of Ven was associated with prolonged survival in patients with RRMM, consistent with the broader MRD body of evidence with other therapies in MM. Clinical trial information: NCT02755597 . [Table: see text]
Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Kumar, Shaji , Popat, Rakesh , Gasparetto, Cristina , Suzuki, Kenshi , Kim, Inho , Punnoose, Elizabeth A. , Hong, Wan‐Jen , Sood, Anjla, Jalaluddin, Muhammad, Pauff, James M., Maciag, Paulo , Harrison, Simon J , Cavo, Michèle , Rubia, Javier de la , Popat, Rakesh , Hungria, Vânia , Salwender, Hans Jürgen , Gay, Francesca , Mikala, Gábor , Jalaluddin, Muhammad, Ross, Jeremy A. , Moreau, Philippe

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 8509-8509

10.1200/jco.2020.38.15_suppl.8509 Get It

8509 Background: Venetoclax (Ven) is a selective, potent, oral BCL-2 inhibitor. In the Phase 3 BELLINI trial, addition of Ven to bortezomib (B) + dexamethasone (d) significantly improved response rates and progression-free survival (PFS) vs placebo (Pbo) and showed significant efficacy in patients (pts) with either t(11;14) or BCL2high gene expression. Here we present updated safety and efficacy data from the prespecified second interim overall survival (OS) analysis. Methods: In this multicenter, randomized, double-blind study (NCT02755597), pts with relapsed/refractory multiple myeloma (RRMM) with 1-3 prior lines of therapy were randomized 2:1 to Ven (800 mg) or Pbo in combination with B (1.3 mg/m2) and d (20 mg). The primary endpoint was PFS; key secondary endpoints included overall response and overall survival (OS). Results: 291 pts were randomized; 194 to Ven, 97 to Pbo. Pt characteristics were well balanced among arms. In the Ven arm, median age was 66, 17% had high-risk cytogenetics, 11% had t(11;14), and 34% had BCL2high gene expression. As of 13 Sept 2019, 59 pts were still on study, 45 (23%) Ven vs 14 (14%) Pbo. At a median follow-up of 28.6 months, there were 64 (33%) deaths in the Ven arm vs 24 (25%) in Pbo. At the initial data cutoff (26 Nov 2018), PFS HR was 0.63 (0.44,0.90) and OS HR was 2.03 (1.04,3.95). Table shows updated PFS and OS. Most common treatment-emergent adverse events (TEAEs) with Ven were diarrhea (59%), nausea (37%), and constipation (35%). Most common grade 3/4 AEs (Ven/Pbo) were neutropenia (21%/8%), thrombocytopenia (15%/30%), anemia (16%/15%), diarrhea (15%/12%), and pneumonia (18%/13%). Serious AEs occurred in 54% Ven and 52% Pbo pts. 24% discontinued Ven due to AEs vs 12% Pbo. There were 14 treatment-emergent deaths in the Ven arm and 1 in Pbo. Conclusions: The addition of Ven to Bd significantly improves PFS but resulted in increased mortality vs Pbo in the total population. Greatest PFS improvement with Ven was observed in pts with t(11;14) or BCL2high gene expression, where Ven shows a favorable benefit-risk profile. The study continues for final OS analysis. Clinical trial information: NCT02755597 . [Table: see text]
Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma.
Hodi, F. Stephen , Kefford, Richard , Patnaik, Amita , Hwu, Wen‐Jen , Gangadhar, Tara C., Dronca, Roxana , Zarour, Hassane M. , Ebbinghaus, Scot, Gergich, Kevin, Li, Xiaoyun , Kang, Soonmo Peter, Hamid, Omid , Ribas, Antoni , Robert, Caroline , Daud, Adil , Wolchok, Jedd D. , Weber, Jeffrey S. , Joshua, Anthony M. , Hersey, Peter , Joseph, Richard W.

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 31 | Issue: 15_suppl | Pages: 9009-9009

10.1200/jco.2013.31.15_suppl.9009 Get It

9009 Background: Programmed death-1 (PD-1) is an inhibitory T-cell co-receptor that may lead to suppression of antitumor immunity. Lambrolizumab is a humanized monoclonal IgG4 antibody against PD-1. This study explored the safety and clinical activity of lambrolizumab in patients (pts) with advanced melanoma (MEL). Methods: In this ongoing phase 1b expansion study of MEL pts with or without previous ipilimumab (IPI) treatment, lambrolizumab was administered IV every 2 or 3 weeks until disease progression or unacceptable toxicity. Tumor response was assessed every 12 weeks by independent, central, blinded radiographic review per immune-related response criteria and RECIST 1.1. Results: As of December 1, 2012, 294 pts with MEL were enrolled, including 179 IPI-naive and 115 IPI-pretreated. Pts received lambrolizumab 10 mg/kg (n = 183) or 2 mg/kg (n = 111). Preliminary data from the first 85 consecutive pts dosed before April 25, 2012, who had independent radiologic review available as of December 3, 2012, indicate a confirmed overall response rate per RECIST 1.1 of greater than 35%, pooled across all doses and schedules and including both IPI-naive and IPI-pretreated patients. The median duration of response has not been reached as only 2 pts who had initial response discontinued due to disease progression, but the duration of confirmed responses range from 28+ to 240+ days (up to 8+ months). Among 133 pts who were dosed with lambrolizumab before July 31, 2012, and evaluable for adverse events (AEs) as of September 28, 2012, fatigue (22%), rash (18%), and pruritus (14%) were the most common drug-related AEs (mostly grade 1/2). The incidence of drug-related grade 3/4 AEs was 10% (24% regardless of attribution). Four drug-related cases of pneumonitis were reported, all of grade 1/2. Grade 3/4 drug-related hypothyroidism (n = 1) and hyperthyroidism (n = 1) were noted. Conclusions: Preliminary data suggest that lambrolizumab has significant antitumor activity and is well tolerated with manageable side effects in both IPI-naive and IPI-pretreated MEL pts. These data have led to an ongoing, international, randomized study of lambrolizumab versus chemotherapy in IPI-pretreated MEL. Clinical trial information: NCT01295827.
Review of 200 consecutive patients with mutation profiling in a lung cancer individualized medicine clinic.
Molina, Julian R. , Jen, Jin , Jang, Jin Sung , Roden, Anja C. , Aubry, Marie‐Christine, Peikert, Tobias, Maldonado, Fabien , Thomas, Charles F., Edell, Eric S. , Lifeng, Wang, Deschamps, Claude, Nichols, Francis C., Cassivi, Stephen D. , Wigle, Dennis A. , Asiedu, Michael K. , Aubry, Marie-Christine, Lifeng, Wang, Yang, Ping , Allen, Mark S. , Shen, Robert K.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: e19013-e19013

10.1200/jco.2013.31.15_suppl.e19013 Get It

e19013 Background: Mutation profiling to assess for potentially druggable mutations in NSCLC is being offered at an increasing number of cancer centers throughout North America and internationally. Although data continue to accumulate for the potential value of mutation testing in designing chemotherapeutic regimens, the treatment impact of obtaining information beyond assessment of EGFR and ALK status remains unclear. How best to obtain and clinically utilize these data, including information from exome and whole genome sequencing, also remains unclear. Methods: Patients were reviewed electronically in a multidisciplinary conference regarding indications for testing and results of mutation profiling from various methods, including the mass-spec based LungCarta test, targeted NexGen sequencing, exome, and whole genome sequencing. Outcomes of the multidisciplinary review were communicated back to treating physicians. Results: Mutation testing was performed on 200 patients using a variety of approaches. The majority (>150) were surgically resected stage I and II tumors. Mutations in at least 1 major cancer driver gene, including EGFR, KRAS, MET, BRAF and PIK3CA, were found in 47% of all patients tested. EGFR mutations were present in 14.8% of patients tested, KRAS 21.3%, BRAF 2.6%, PIK3CA 3.2%, and MET 4.5%. A total of 8 patients underwent either exome or whole genome sequencing. A limited number of patients (<10) had mutation results that impacted treatment decisions from this cohort. Conclusions: Mutation profiling can influence treatment decisions in NSCLC, but at a low frequency. The role of exome and or whole genome sequencing for patients with NSCLC is evolving and remains undefined.